$TMO (-0,89 %) | Thermo Fisher Scientific Q3'24 Earnings Highlights:

🔹 Adj EPS: $5.28 (Est. $5.25) 🟢; DOWN -7.2% YoY

🔹 Revenue: $10.60B (Est. $10.65B) 🔴; UP +0.2% YoY

FY24 Guidance:

🔹 Revenue: $42.48B-$43.38B (Est. $42.91B) 🟡

🔹 Adjusted EPS: $21.35-$22.07 (Est. $21.72) 🟢

Q3 Segment Performance:

🔹 Life Sciences Revenue: $2.39B (Est. $2.46B) 🔴; DOWN -1.9% YoY

Operational Metrics (GAAP):

🔹 EPS: $4.25 (Prev. $4.42 YoY)

🔹 Operating Income: $1.84B (Prev. $1.86B YoY)

🔹 Operating Margin: 17.3% (Prev. 17.6% YoY)

🔹 Adj Operating Income: $2.36B

🔹 Adj Operating Margin: 22.3% (Prev. 24.2% YoY)

New Product Launches:

🔸 Thermo Scientific Iliad Microscope: Advances research in modern materials.

🔸 Applied Biosystems MagMAX DNA/RNA Kit: Enhances genetic research in blood cancers.

🔸 Vivofectamine Delivery Solutions: Enables nucleic acid delivery for new therapeutic applications.

Strategic Initiatives:

🔸 Partnership with the National Cancer Institute for next-gen sequencing in precision medicine.

🔸 Expansion of pharma services in Cincinnati, Ohio, and Bend, Oregon.

🔸 New bioanalytical lab in Gothenburg, Sweden, to support biotech R&D.

CEO Marc N. Casper's Commentary:

🔸 "We delivered strong financial results, reflecting sequential growth improvement. With our growth strategy and trusted partnerships, we are well-positioned to meet our 2024 objectives and build long-term value."